Vascular endothelial growth factor is a strong predictor of early distant recurrences in a prospective study of premenopausal women with lymph-node negative breast cancer
- PMID: 18508268
- DOI: 10.1016/j.breast.2008.02.010
Vascular endothelial growth factor is a strong predictor of early distant recurrences in a prospective study of premenopausal women with lymph-node negative breast cancer
Erratum in
- Breast. 2009 Apr;18(2):142. Gruvbreger-Saal, Sofia [corrected to Gruvberger-Saal, Sofia]
Abstract
We investigate the prognostic significance of the pro-angiogenic cytokine vascular endothelial growth factor (VEGF), urokinase-type plasminogen activator (uPA), plasminogen activator inhibitor 1 (PAI-1), and S-phase fraction (SPF) for distant disease free survival (DDFS) in 219 premenopausal patients with node-negative breast cancer (NNBC). In univariate analysis significantly shorter DDFS was observed for patients with high VEGF (p=0.006), high uPA (p=0.001), and high SPF (p<0.001). The prognostic significance of VEGF varied over time being very strong for early relapses (0-2.25 years follow-up) (HR=7.9; p=0.006) while no difference was seen in the subsequent follow-up period (HR=1.3; p=0.62). In a series of bivariate analyses VEGF provided prognostic information during the whole observation period (0-72 months) in addition to age, tumour size, oestrogen receptor (ER), progesterone receptor (PgR), and uPA. Also this effect was more pronounced during the first follow-up period suggesting VEGF as a marker of early recurrences.
Similar articles
-
S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer.J Clin Oncol. 2001 Apr 1;19(7):2010-9. doi: 10.1200/JCO.2001.19.7.2010. J Clin Oncol. 2001. PMID: 11283134
-
Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.Cancer. 2004 Aug 1;101(3):486-94. doi: 10.1002/cncr.20374. Cancer. 2004. PMID: 15274061
-
Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).Cancer Res. 2002 Aug 15;62(16):4617-22. Cancer Res. 2002. PMID: 12183417
-
Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.Thromb Haemost. 2004 Mar;91(3):450-6. doi: 10.1160/TH03-12-0798. Thromb Haemost. 2004. PMID: 14983219 Review.
-
Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers.Biochem Soc Trans. 2002 Apr;30(2):207-10. Biochem Soc Trans. 2002. PMID: 12023852 Review.
Cited by
-
Association between the Functional Polymorphism of Vascular Endothelial Growth Factor Gene and Breast Cancer: A Meta-Analysis.Iran J Med Sci. 2015 Jan;40(1):2-12. Iran J Med Sci. 2015. PMID: 25649829 Free PMC article. Review.
-
Pin1-Nanog expression in human glioma is correlated with advanced tumor progression.Oncol Rep. 2013 Aug;30(2):560-6. doi: 10.3892/or.2013.2481. Epub 2013 May 23. Oncol Rep. 2013. PMID: 23708493 Free PMC article.
-
High-risk early breast cancer in patients under 40 years of age: Improved clinical outcome with total estrogen blockade and tailored chemotherapy.Exp Ther Med. 2010 Sep;1(5):867-872. doi: 10.3892/etm.2010.135. Epub 2010 Jul 21. Exp Ther Med. 2010. PMID: 22993611 Free PMC article.
-
Overexpression of Nanog protein is associated with poor prognosis in gastric adenocarcinoma.Med Oncol. 2012 Jun;29(2):878-85. doi: 10.1007/s12032-011-9860-9. Epub 2011 Feb 20. Med Oncol. 2012. PMID: 21336986
-
The association between vascular endothelial growth factor expression in invasive breast cancer and survival varies with intrinsic subtypes and use of adjuvant systemic therapy: results from the Nurses' Health Study.Breast Cancer Res Treat. 2011 Aug;129(1):175-84. doi: 10.1007/s10549-011-1432-3. Epub 2011 Mar 9. Breast Cancer Res Treat. 2011. PMID: 21390493 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous